Clinical trial · Observational
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
NCT01652560CI-TRIAL-00007597BIBCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
\- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bevacizumab | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Molecular Targeted Therapy | — | UNRESOLVED | — |
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- bevacizumab combined neoadjuvant chemotherapy
- interventionNames
- Drug: bevacizumab
Primary outcomes (1)
- measure
- Objective Response Rate
- timeFrame
- From enrollment to disease progression
- description
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Secondary outcomes (1)
- measure
- overall response
- timeFrame
- From enrollment to disease progression
- description
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * HER2-negative breast cancer patients * Without surgery * Plans to neoadjuvant chemotherapy Exclusion Criteria: * HER2-positive breast cancer patients * Post-operative patients
References
Publications (0)
Data not yet available
No reference posted for this study.